Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.

from Latest articles from Cancer Therapy Advisor Skin Cancer https://ift.tt/2OWU8W3